Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease

Ann Hematol. 2015 Jul;94(7):1241-3. doi: 10.1007/s00277-015-2353-8. Epub 2015 Mar 21.

Authors

Linus Angenendt¹, Andrea Kerkhoff, Stefanie Wiebe, Jan-Henrik Mikesch, Annika Rudat, Fabian Wötzel, Christian Wenning, Christoph Schliemann, Torsten Kessler, Michael Schäfers, Eva Wardelmann, Matthias Stelljes, Wolfgang E Berdel

Affiliation

¹ Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany, angenendt@uni-muenster.de.

PMID: 25791243
DOI: 10.1007/s00277-015-2353-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
Castleman Disease / diagnosis*
Castleman Disease / therapy*
Humans
Male
Remission Induction
Rituximab
Severity of Illness Index*
Stem Cell Transplantation / trends*
Transplantation, Homologous / trends

Substances

Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Rituximab
tocilizumab

Supplementary concepts

Multi-centric Castleman's Disease